Satellos Bioscience Inc.
MSCL.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -108.95% | -59.06% | -63.89% | 12.12% | -26.76% |
| Total Depreciation and Amortization | -- | 0.00% | -100.00% | 50.00% | -100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 113.00% | 39.59% | 1,906.98% | -70.97% | 70.23% |
| Change in Net Operating Assets | 758.62% | 61.93% | -1.38% | 149.38% | 370.34% |
| Cash from Operations | -65.77% | -30.12% | -39.23% | -27.42% | -13.21% |
| Capital Expenditure | 100.00% | -- | -- | -- | 0.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -139.41% | -- | 71.39% | -218.15% | 325.45% |
| Cash from Investing | -139.42% | -- | 71.39% | -218.17% | 325.94% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.34% | 2,362,450.00% | -99.52% | 311.76% | 11,500.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.34% | 2,594,950.00% | -99.61% | 311.76% | 11,500.00% |
| Foreign Exchange rate Adjustments | -94.42% | -2,966.67% | 132.33% | -150.82% | 296.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -305.34% | 220.81% | -141.83% | -285.22% | 318.19% |